NCT00159250View on ClinicalTrials.gov

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 26, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

AVI-4658 (PMO)

morpholino antisense oligonucleotide

Trial Locations (1)

W12 0HS

Dubowitz Neuromuscular Centre, Hammersmith Hospital and Clinical Trails Unit, St Mary's Hospital, London

All Listed Sponsors
collaborator

Department of Health, United Kingdom

OTHER_GOV

collaborator

Sarepta Therapeutics, Inc.

INDUSTRY

lead

Imperial College London

OTHER

NCT00159250 - Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter